FDA Replaces Avandia REMS Distribution Restrictions With Prescriber Training
This article was originally published in The Pink Sheet Daily
Comforted by the re-adjudicated RECORD results, agency directs rosiglitazone sponsors to provide training “based on the current state of knowledge” about the diabetes drug’s cardiovascular risk but eliminates the requirement that links drug access to provider, pharmacy and patient enrollment in the REMS.
You may also be interested in...
Can A REMS Mitigate CV Risks? Avandia, Meridia Offer Point, Counterpoint
As US FDA weighs fate of Takeda’s febuxostat, advisory committee members suggest REMS to ensure prescribers have informed benefit/risk conversation with patients, but agency staff highlight design and assessment challenges for such a program.
Melior, Bukwang Seek Diabetes Edge With Novel Insulin Sensitizer
MLR-1023, a repositioned oral compound being developed for type 2 diabetes by Melior and Bukwang, is set to move into Phase IIb in the US and South Korea, and the firms are looking to its novel mechanism of action, improved tolerability and efficacy to carve a niche in a highly competitive sector.
When To End A REMS? Soliris Review Stirs Debate On How To Scale Back
Risk management program for Alexion’s orphan drug eculizumab appears to be succeeding, but what does FDA need to see to make it less burdensome?